For the year, the company posted total revenues of 312 million euros ($367 million U.S.), up from 283 million euros ($333 million) in 2019, boosted largely by its strategic licensing deal with CGN Nuclear Technology, according to the company.
Company representatives reported Asia as a key strategic growth market, particularly China, where IBA signed significant proton therapy deals in the second half of 2020. The company also reported strong sales in the region for its industrial, radiopharma, and dosimetry businesses.
In addition, IBA reported total group net profit of 31.9 million euros ($37.6 million), compared with 7.6 million euros ($8.9 million) in 2019.
Copyright © 2021 AuntMinnie.com